
A leading provider of
innovative DNA Screening solutions
CHARGE syndrome is an autosomal dominant disorder that occurs in 1/10, 000 births. The acronym CHARGE summarizes six main clinical features: ocular Coloboma, Heart defects of any type, Atresia of the choaneae, Retardation, Genital and Ear anomalies1. The gene CHD7 was identified as causative for the syndrome in 2/3 of patients with a clinical diagnosis of CHARGE. CD7 is located in 8q12.1 and is 188 kb in size. Most mutations are truncating mutations, leading to haploinsufficiency and are mostly de novo. They are found in 53-65% of patients with the syndrome. Microdeletions are found in up to 10% of CHARGE patients 2,3. The CDH7 protein plays role in chromatin organization and is a member of the chromodomain helicase DNA-binding (CDH) genes. The CDH7 has an important function in early embryonic development. It is ubiquitously expressed in several fetal and adult tissues, including those affected in CHARGE syndrome 2.
Cat. No. LPU 021-S (5 tests)
Cat. No. LPU 021 (10 tests)
These products are only available labelled as Analyte Specific Reagents (ASR) in the USA.
Developed &